IP Library Granted Patent US 12,280,146
Granted Patent B2
US 12,280,146 · App. 18/533,497 · Granted Apr 22, 2025

Nanoemulsion without propylene glycol

Inventors: Montserrat Foguet (Leverkusen, DE); Lars Möllmann (Leverkusen, DE)
Assignee: Biofrontera Bioscience GmbH
A61K9/1075A61K9/127A61K41/0061A61K47/10A61K47/12A61K47/14A61K47/24A61K47/26A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,280,146
App. No.
18/533,497
Granted
Apr 22, 2025
Kind
B2
Abstract

The present invention relates to oil in water nanoemulsions which are essentially free of propylene glycol. The nanovesicle formulations are particularly stable in regard to shelf life at different storage temperatures.

Claims (25)

1. A formulation comprising:

(a) a nanoemulsion comprising:

(i) at least one aqueous component;

(ii) a carrier component comprising:

(1) at least one lipophilic component,

(2) at least one surfactant, and

(3) at least one alcohol; and

(b) 5-aminolevulinic acid and/or a derivative, a precursor, a metabolite, and/or a pharmaceutically acceptable salt thereof,

wherein the formulation comprises essentially no propylene glycol and essentially no sorbitol.

2. The formulation of claim 1 , wherein the formulation further comprises less than 1% w/w of a non-cyclic polyol having 2 to 5 carbon atoms.

3. The formulation of claim 1 , wherein the formulation further comprises less than 1% w/w of a non-cyclic polyol having 2 to 12 carbon atoms.

4. The formulation of claim 1 , wherein the at least one alcohol comprises: 3, 4, or 5 carbon atoms; or 1-propanol, 2-propanol, or a mixture thereof.

5. The formulation of claim 1 , comprising the at least one aqueous component in an amount from 50% to 99% (w/w), from 70% to 95% (w/w), from 75% to 95% (w/w), or from 80% to 90% (w/w).

6. The formulation of claim 4 , comprising the at least one lipophilic component in an amount from 0.1% to 30% (w/w), from 0.25% to 15% (w/w), from 0.25% to 10% (w/w), from 2% to 10% (w/w), or 3% to 8% (w/w) based on total weight of the nanoemulsion.

7. The formulation of claim 1 , wherein the formulation comprises no propylene glycol.

8. The formulation of claim 1 , wherein the formulation further comprises less than or equal to 0.99%, 0.95%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% w/w of a non-cyclic polyol having 2 to 5 carbon atoms.

9. The formulation of claim 1 , wherein the formulation further comprises essentially no non-cyclic polyol having 2 to 5 carbon atoms.

10. The formulation of claim 1 , wherein the formulation further comprises no non-cyclic polyol having 2 to 5 carbon atoms.

11. The formulation of claim 1 , wherein the formulation further comprises less than or equal to 0.99%, 0.95%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% w/w of a non-cyclic polyol having 2 to 12 carbon atoms.

12. The formulation of claim 1 , wherein the formulation further comprises essentially no non-cyclic polyol having 2 to 12 carbon atoms.

13. The formulation of claim 1 , wherein the formulation further comprises no non-cyclic polyol having 2 to 12 carbon atoms.

14. The formulation of claim 1 , wherein the at least one lipophilic component comprises: triglycerides and/or mixtures thereof; or a caprylic triglyceride, a capric triglyceride, or a mixture thereof.

15. The formulation of claim 1 , wherein the at least one surfactant comprises: a phospholipid, a phosphatidylcholine, a lysophospholipid, a ceramide, and/or a mixture thereof; and/or a polyoxyethylene-type surfactant.

16. The formulation of claim 4 , wherein the at least one alcohol is in an amount from 0.1% to 10% (w/w), from 0.5% to 5% (w/w), from 1% to 5% (w/w), or from 1% to 3% based on total weight of the nanoemulsion.

17. The formulation of claim 1 , wherein the formulation further comprises essentially no monosaccharides and disaccharides.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE PREVIOUSLY RECORDED ON REEL 73509 FRAME 6. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 8, 2026
From: BIOFRONTERA BIOSCIENCE GMBH
To: BIOFRONTERA, INC.
Reel/Frame 075699/0753 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2025
From: BIOFRONTERA BIOSCIENCE GMBH
To: BIOFRONTERA, INC.
Reel/Frame 073509/0006 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2024
From: FOGUET, MONTSERRAT; MÖLLMANN, LARS
To: BIOFRONTERA BIOSCIENCE GMBH
Reel/Frame 066258/0610 →
Priority Claims (1)
WO PCT/EP2023/059291 · Apr 6, 2023 · international
Continuity (1)
Related Publication 20240335380A1 · Oct 10, 2024
References Cited (63)
US 5152923A · Weder · 1992 [cited by examiner]
US 5891490A · Merabet · 1999 [cited by applicant]
US 6165500A · Cevc · 2000 [cited by applicant]
US 6245349B1 · Yiv et al. · 2001 [cited by applicant]
US 6274150B1 · Simonnet et al. · 2001 [cited by applicant]
US 6375960B1 · Simonnet et al. · 2002 [cited by applicant]
US 6413527B1 · Simonnet et al. · 2002 [cited by applicant]
US 6500862B1 · Zanello · 2002 [cited by applicant]
US 6559183B1 · Schmid · 2003 [cited by examiner]
US 6602511B2 · Von Corswant · 2003 [cited by applicant]
US 6897238B2 · Chen et al. · 2005 [cited by applicant]
US 7314624B2 · Baker et al. · 2008 [cited by applicant]
US 11540981B2 · Roca et al. · 2023 [cited by applicant]
US 20020155084A1 · Roessler et al. · 2002 [cited by applicant]
US 20030148927A1 · Patt et al. · 2003 [cited by applicant]
US 20030167033A1 · Chen et al. · 2003 [cited by applicant]
US 20030190347A1 · Supersaxo et al. · 2003 [cited by applicant]
US 20050158389A1 · Domb · 2005 [cited by applicant]
US 20050208083A1 · Annis · 2005 [cited by applicant]
US 20060078525A1 · Tomokuni · 2006 [cited by applicant]
US 20060140984A1 · Tamarkin et al. · 2006 [cited by applicant]
US 20090110703A1 · Tolla et al. · 2009 [cited by applicant]
US 20090324727A1 · Foguet Roca · 2009 [cited by examiner]
US 20110060042A1 · Ito · 2011 [cited by applicant]
US 20230201087A1 · Roca et al. · 2023 [cited by applicant]
EP 0620271A1 · 1994 [cited by applicant]
EP 0704209A1 · 1996 [cited by applicant]
EP 1473367A1 · 2004 [cited by applicant]
EP 1655021A1 · 2006 [cited by applicant]
JP 2002302414A · 2002 [cited by applicant]
JP 2006273821A · 2006 [cited by applicant]
WO WO1996041647A1 · 1996 [cited by applicant]
WO WO1997041855A1 · 1997 [cited by applicant]
WO WO1998021307A1 · 1998 [cited by applicant]
WO WO2002066589A2 · 2002 [cited by applicant]
WO WO2005027872A2 · 2005 [cited by applicant]
WO WO2005110370A1 · 2005 [cited by applicant]
U.S. Appl. No. 12/520,759 2009/0324727 U.S. Pat. No. 11,540,981, filed Dec. 22, 2006 Dec. 21, 2007 Jan. 3, 2023, Montserrat Foguet Roca, Nanoemulsion Formulation with Improved Stability and Cell Penetration. [cited by applicant]
U.S. Appl. No. 18/071,733 2023/0201087, filed Nov. 30, 2022 Jun. 29, 2023, Montserrat Foguet Roca, Nanoemulsion. [cited by applicant]
U.S. Appl. No. 18/533,521, filed Dec. 8, 2023, Montserrat Fouget, Pressurized Nanoemulsion. [cited by applicant]
Aboofazeli et al., “Particle Size Analysis of Concentrated Phospholipid Microemulsions: I. Total Intensity Light Scattering”, AAPS PharmSci, 2000, 2(2): 1-13. [cited by applicant]
Alam et al., “Design and Characterization of Nanostructured Topical Gel of Betamethasone Dipropionate for Psoriasis,” Journal of Applied Pharmaceutical Science, 2012, 2(10): 148-158. [cited by applicant]
Bagwe et al., “Improved Drug Delivery Using Microemulsions: Rationale, Recent Progress, and New Horizons”, Critical Reviews in Therapeutic Drug Carrier Systems, 2001, 18(1): 77-140. [cited by applicant]
Binks et al., “Phase Behaviour of microemulsions stabilised by double chain cationic surfactants and alcohol co-surfactants”, Colloids and Surfaces A: Physicochem. Eng. Aspects, Jan. 23, 2003, 212(2-3): 135-145. [cited by applicant]
Danielsson et al., “The Definition of Microemulsion”, Colloids and Surfaces, Dec. 1981, 3(4): 391-392. [cited by applicant]
Fendler et al., “Liposomes as Drug Carriers”, Life Sciences, Apr. 1, 1977, 20(7):1109-1120. [cited by applicant]
Fritsch et al., “Fluorescence Diagnosis and Photodynamic Therapy of Skin Diseases”, Atlas and Handbook, 2003, pp. 23-31. [cited by applicant]
International Food Information Service, “Dictionary of Food Science and Technology”, 2nd ed. 2009, p. 250. [cited by applicant]
International Search Report and Written Opinion for PCT International Patent Application No. PCT/EP2007/011404, dated May 9, 2008. [cited by applicant]
Kang et al., “Preparation and Characterization of Nano-Liposomes Using Phosphatidylcholine”, International Journal of Industrial and Engineering Chemistry, Nov. 2005, 11(6): 847-851. [cited by applicant]
Kosar et al., “Exogenously-applied 5-aminolevulinic acid modulates some key physiological characteristics and antioxidative defense system in spring wheat ( [cited by applicant]
Moreno, “Lecithin-Based Oil-in-Water Microemulsions for Parenteral Use: Pseudoternary Phase Diagrams, Characterization and Toxicity Studies”, Wiley-Liss Journal of Pharmaceutical Science, 2003, 92(7): 1428-1437. [cited by applicant]
O'Neil et al., “The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals,” Merck & Co., Inc.; entries for “aminolevulinic acid,” “Lecithins,” and “Polysorbates,” 2006, pp. 1-8 (as provided). [cited by applicant]
Sarker, “Engineering of Nanoemulsions for Drug Delivery”, Current Drug Delivery, Oct. 2005, 2(4): 297-310. [cited by applicant]
Sinko et al., “Martin's Physical Pharmacy and Pharmaceutical Sciences”, Physical Chemical and Biopharmaceutical Principles in the Pharmaceutical Sciences, 15th ed., 2009, Chapter 18, “Coarse Dispersions” pp. 499-530. [cited by applicant]
Sonneville-Aubrun et al., “Nanoemulsions: a new vehicle for skincare products”, Advanced Colloid and Interface Science, May 20, 2004, 108-109: 145-149. [cited by applicant]
Suppasansatorn et al., “Microemulsions as topical delivery vehicles for the anti-melanoma prodrug, temozolomide hexyl ester (TMZA-HE)”, Journal of Pharmacy and Pharmacology, Jun. 2007, vol. 59, pp. 787-794. [cited by applicant]
Tadros et al., “Formation and stability of nano-emulsions”, Advances in Colloid and Interface Science, May 20, 2004, vol. 108-109, pp. 303-318. [cited by applicant]
Weiss et al., “Nanostructured Encapsulation Systems: Food Antimicrobials”, Global Issues in Food Science and Technology, 2009, Chapter 24, pp. 425-479. [cited by applicant]
Yuan et al., “Investigation of microemulsion system for transdermal delivery of meloxicam”, International Journal of Pharmaceutics, Sep. 14, 2006, 321(1-2):117-123. [cited by applicant]
Acharaya et al., “Physicochemical Investigations of Microemulsification of Coconut Oil and Water Using Polyoxyethylene 2-Cetyl Ether (Brij 52) and Isopropanol or Ethanol”, Journal of Colloid and Interface Science, 2002,… [cited by applicant]
Changez et al., “Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: In vitro”, Colloids a… [cited by applicant]
De Spiegeleer et al., “The Importance of the Cosolvent Propylene Glycol on the Antimicrobial Preservative Efficacy of a Pharmaceutical Formulation by DOE—Ruggedness Testing”, Informa Healthcare; Pharmaceutical Developme… [cited by applicant]